Latest Content

The A-NEW study found that 42% of breast cancer survivors with slower early weight loss reached the 5% goal after Contrave was added.

FDA approves BESREMi for adults with essential thrombocythemia, offering a new treatment option for people living with this rare blood cancer.

FDA approves Mimrylo (rusfertide) for adults with polycythemia vera, offering a new treatment approach that may reduce the need for frequent blood draws.

After breast cancer treatment ends, survivorship can bring unexpected challenges. One survivor shares how she learned to heal and redefine who she is.

A stage IV kidney cancer survivor shares how 10 years of treatment changed his view of success, uncertainty, fear and finding meaning in everyday life.

Ivonescimab plus chemotherapy improved survival compared with Imfinzi plus chemotherapy in patients with previously untreated advanced biliary tract cancer, according to phase 3 findings.

A breast cancer survivor reflects on managing lymphedema, navigating Dupuytren’s disease and finding perspective when new health challenges arise.

Theresa Gannon’s compassion, leadership and dedication to patients and fellow oncology nurses make her an Extraordinary Healer Award nominee.

Dr. Maria Margarete Karsten discusses how weekly symptom monitoring helped identify changes between visits and what patients told her about using it.

Jim Day was told he had six months to live after a stage 4 melanoma diagnosis. A cancer-fighting virus helped shrink his tumors and gave him hope.

A UCLA study found patients with cancer who used biosimilars paid less out of pocket, and their insurers paid far less, than those on brand-name biologics.

Researchers are studying how genetics and environmental factors may influence lung cancer risk and could help shape the future of screening and treatment.

In the phase 2/3 STAR-TREC trial, 78.5% of patients given long-course chemoradiotherapy kept their rectum at 12 months, versus 60.6% with short-course radiotherapy.